Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd (SHA:600671)

SHA:600671 Financials Overview

Financials in millions CNY. Fiscal year is January - December.

Revenue & Profits

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue Revenue Growth	207.51	211.75	217.3	121.78	108.91	147.07
Revenue Growth	-20.60%	-2.55%	78.44%	11.82%	-25.95%	-28.82%
Gross Profit Gross Profit Growth	107.1	100.16	100.68	23.41	15.16	40.62
Operating Income Operating Income Growth	17.33	14.04	29.44	-22.5	-43.89	-29.19
Net Income Net Income Growth	13.68	17.62	15.25	-38.28	-67.52	-29.8
Earnings Per Share EPS Growth	0.11	0.14	0.13	-0.31	-0.55	-0.24
EPS Growth	-68.92%	15.57%	-	-	-	-

Revenue by Segment

Chart

Fiscal Year	FY 2025
Period Ending	Dec 31, 2025
Chinese Patent Medicine Chinese Patent Medicine Growth	28.26
Chemical Medicine Chemical Medicine Growth	1.84
Active Pharmaceutical Ingredient (API) Active Pharmaceutical Ingredient (API) Growth	30.3
Health Care Products Health Care Products Growth	90.99
Circulating Commodities Circulating Commodities Growth	50.35
Medical Instruments Medical Instruments Growth	3.79
Service Type Service Type Growth	5.19
Other Other Growth	0.98
Total Total Growth	211.7

Cash & Debt

Chart

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Investments Cash & Investments Growth	70.11	31.89	65.72	97.96	42.39	22.29
Total Debt Total Debt Growth	189.76	165.79	152.35	114.61	116.04	113.7
Net Cash (Debt) Net Cash Growth	-119.66	-133.91	-86.63	-16.65	-73.65	-91.41
Net Cash Growth	-	-	-	-	-	-
Net Cash Per Share Net Cash Per Share Growth	-0.98	-1.10	-0.71	-0.14	-0.60	-0.74

Cash Flow & CapEx

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Operating Cash Flow Operating Cash Flow Growth	46.95	11.79	-36.67	-20.43	-19.37	-26.42
Capital Expenditures CapEx Growth	-19.15	-31.18	-20.55	-8.96	-3.52	-4.71
Free Cash Flow Free Cash Flow Growth	27.8	-19.39	-57.23	-29.38	-22.89	-31.13
Free Cash Flow Growth	-	-	-	-	-	-

Margins

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Gross Margin	51.61%	47.30%	46.33%	19.23%	13.92%	27.62%
Operating Margin	8.35%	6.63%	13.55%	-18.48%	-40.30%	-19.85%
Pretax Margin	5.49%	4.83%	13.38%	-29.82%	-66.45%	-22.94%
Profit Margin	6.59%	8.32%	7.02%	-31.43%	-62.00%	-20.26%
FCF Margin	13.40%	-9.16%	-26.34%	-24.13%	-21.02%	-21.17%

Valuation

Chart

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 14, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
PE Ratio	200.50	119.62	70.13	-	-	-
PS Ratio	13.22	9.96	4.92	11.66	10.63	7.44

Data Source: S&P Global Market Intelligence Last updated: Aug 27, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Sep 14, 2026

Data Sources Report a data error